Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    StockNews24StockNews24
    Subscribe
    • Shares
    • News
      • Featured Company
      • News Overview
        • Company news
        • Expert Columns
        • Germany
        • USA
        • Price movements
        • Default values
        • Small caps
        • Business
      • News Search
        • Stock News
        • CFD News
        • Foreign exchange news
        • ETF News
        • Money, Career & Lifestyle News
      • Index News
        • DAX News
        • MDAX News
        • TecDAX News
        • Dow Jones News
        • Eurostoxx News
        • NASDAQ News
        • ATX News
        • S&P 500 News
      • Other Topics
        • Private Finance News
        • Commodity News
        • Certificate News
        • Interest rate news
        • SMI News
        • Nikkei 225 News1
    • Carbon Markets
    • Raw materials
    • Funds
    • Bonds
    • Currency
    • Crypto
    • English
      • العربية
      • 简体中文
      • Nederlands
      • English
      • Français
      • Deutsch
      • Italiano
      • Português
      • Русский
      • Español
    StockNews24StockNews24
    Home » Kyverna Therapeutics, Inc. (KYTX) Investors: February 7, 2025 Filing Deadline in Securities Class Action
    News

    Kyverna Therapeutics, Inc. (KYTX) Investors: February 7, 2025 Filing Deadline in Securities Class Action

    userBy userJanuary 5, 2025No Comments3 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email



    RADNOR, PA – (NewMediaWire) – January 5, 2025 – The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (Kyverna) (NASDAQ: KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyvernas February 8, 2024 initial public offering (IPO). The lead plaintiff deadline is February 7, 2025.

    CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:

    If you suffered Kyverna losses, you may CLICK HERE or copy and paste this link into your browser: https://www.ktmc.com/new-cases/kyverna-therapeutics-inc?utm_source=PR&utm_medium=link&utm_campaign=kytx&mktm=r

    You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ktmc.com .

    DEFENDANTS ALLEGED MISCONDUCT:

    The complaint alleges that, in the prospectus and registration statements issued in connection with the IPO, Defendants made materially false and/or misleading statements and/or omissions regarding the companys business, operations, and prospects. Specifically, Defendants made false and/or misleading statements regarding, and/or failed to disclose, that Kyverna possessed adverse data related to one of its clinical trials at the time of its IPO.

    THE LEAD PLAINTIFF PROCESS:

    Kyverna investors may, no later than February 7, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

    Kessler Topaz Meltzer & Check, LLP encourages Kyverna investors who have suffered significant losses to contact the firm directly to acquire more information.

    CLICK HERE TO SIGN UP FOR THE CASE OR COPY AND PASTE THIS LINK INTO YOUR BROWSER: https://www.ktmc.com/new-cases/kyverna-therapeutics-inc?utm_source=PR&utm_medium=link&utm_campaign=kytx&mktm=r

    ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:

    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com .

    CONTACT:

    Kessler Topaz Meltzer & Check, LLP

    Jonathan Naji, Esq.

    (484) 270-1453

    280 King of Prussia Road

    Radnor, PA 19087

    info@ktmc.com

    May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

    View the original release on www.newmediawire.com

    Copyright 2025 JCN Newswire . All rights reserved.





    Source link

    Share this:

    • Click to share on Facebook (Opens in new window) Facebook
    • Click to share on X (Opens in new window) X

    Like this:

    Like Loading...

    Related

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleWhy more NFL teams might pivot to private equity in 2025
    Next Article Trump, Fed Seen Risking $127 Billion Bond Spree in Latin America
    user
    • Website

    Related Posts

    Apple paying $95 million in a Siri eavesdropping settlement. Here’s how to file a claim.

    May 13, 2025

    S&P 500 jumps, set to wipe out 2025 losses as Dow weighed down by UnitedHealth plunge

    May 13, 2025

    I bought 1,779 Legal & General shares 2 years ago – see how much dividend income I’ve got since

    May 13, 2025
    Add A Comment

    Leave a ReplyCancel reply

    © 2025 StockNews24. Designed by Sujon.

    Type above and press Enter to search. Press Esc to cancel.

    %d